Structure Therapeutics (NASDAQ:GPCR) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Structure Therapeutics (NASDAQ:GPCR) to a strong-buy rating in a research report released on Monday,Zacks.com reports.

Several other equities analysts have also recently weighed in on GPCR. JMP Securities decreased their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. Guggenheim decreased their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. HC Wainwright decreased their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and a consensus price target of $75.71.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $20.89 on Monday. The stock has a 50 day simple moving average of $18.89 and a 200 day simple moving average of $20.68. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $45.37. The firm has a market capitalization of $1.20 billion, a PE ratio of -19.90 and a beta of -1.88.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08). Equities research analysts predict that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in Structure Therapeutics by 663.8% during the 1st quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock valued at $152,000 after purchasing an additional 7,627 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Structure Therapeutics during the 4th quarter valued at $304,000. Cubist Systematic Strategies LLC lifted its holdings in Structure Therapeutics by 3,326.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company’s stock valued at $949,000 after purchasing an additional 53,216 shares during the last quarter. Jump Financial LLC acquired a new stake in Structure Therapeutics during the 1st quarter valued at $532,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Structure Therapeutics during the 4th quarter valued at $3,091,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.